S&P Futures
4,017.00 +15.50 (+0.39%) Dow Futures
32,696.00 +108.00 (+0.33%) Nasdaq Futures
12,773.50 +41.00 (+0.32%) Russell 2000 Futures
1,775.00 +10.20 (+0.58%) Crude Oil
73.64 +0.44 (+0.60%) Gold
1,970.00 -3.50 (-0.18%)
BrainsWay Ltd. (BWAY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7500 |
| Open | 1.7500 |
| Bid | 1.6000 x 3000 |
| Ask | 1.8300 x 1000 |
| Day's Range | 1.7500 - 1.8450 |
| 52 Week Range | 1.6400 - 9.1800 |
| Volume | |
| Avg. Volume | 85,330 |
| Market Cap | 30.022M |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.05 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BWAY
Related Research
- Brainsway Ltd.Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called Transcarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device is deployed to temporarily reverse blood flow to the brain in order to prevent any broken off clots from moving to the brain.RatingFair ValueEconomic Moatlast yearArgus Research
- GlobeNewswire
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of an expansive post-marketing data analysis demonstrating high response and remission rates for depression and anxious depression pat
- GlobeNewswire
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results and provided an operational update. Recent Financial and Operational Highlights For the three months ended December 31, 2022, revenues were $6.0 million, a 29% decrease as compared to the prior year period.As of December
- GlobeNewswire
BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies
Joins the Ranks of OpenAI, Disney, and Tiffany & Co.BURLINGTON, Mass. and JERUSALEM, March 02, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023. This year’s list highlights the businesses at the forefront of their respective in
